Aptose Biosciences

Ver el organigrama con sus 18 ejecutivos principales

Biografías más buscadas en Aptose Biosciences

• William Rice, Chairman, President and Chief Executive Officer
• Erich Platzer, Director
• Warren Whitehead, Director

Recientes movimientos de ejecutivos en Aptose Biosciences

• Fletcher Payne que ha sido Senior Vice President and Chief Financial Officer, ha ascendido a Senior Vice President, Chief Financial Officer and Chief Business Officer  (noticia publicada el 4 de diciembre de 2023).

Crear su alerta
para seguir los movimientos de los ejecutivos en Aptose Biosciences.

Aptose Biosciences tiene 2.276 competidores entre los que se incluyen Eurofins (Luxemburgo), Lonza (Suiza) y Adaptive Phage Therapeutics (Estados Unidos).

Popular M&A news in Biotecnología

• Histogen has filed for bankruptcy protection  (publicado el 19 de abril de 2024).
• Bruker has announced the acquisition of NanoString Technologies  (publicado el 18 de abril de 2024).
• Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences  (publicado el 16 de abril de 2024).

Otros contactos sugeridos en el sector Biotecnología

• Ali Behbahani - Non-Executive Director en Adaptimmune Therapeutics
• Vik Bajaj - Director en Interline Therapeutics
• Khalil Barrage - Interim Chairman of the Board en Sensorion

Saber más sobre el sector Biotecnología >

Últimos comunicados de prensa de Aptose Biosciences

• Aptose Reports Results for the Fourth Quarter and Full Year 2023
• Press Releases
• Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024
• Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical
• Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting
• Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role
• Aptose Reports Results for the Third Quarter 2023
• Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting
• Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th
• Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib
• View more press releases Close

Redes sociales sobre Aptose Biosciences

• Aptose Biosciences en Wikipedia, Google News y Yahoo Finance
• Aptose Biosciences en LinkedIn, Twitter y YouTube

Contactar a través de e-mail con sus ejecutivos William Rice

Llame a Aptose Biosciences al +1 416...

Ver el organigrama

Register to receive your alert

Señalar un error